Leerink Partnrs Weighs in on NeuroPace FY2029 Earnings

NeuroPace, Inc. (NASDAQ:NPCE) – Leerink Partnrs issued their FY2029 EPS estimates for shares of NeuroPace in a note issued to investors on Tuesday, January 28th. Leerink Partnrs analyst M. Kratky forecasts that the company will post earnings per share of $0.43 for the year. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The company had revenue of $21.06 million for the quarter, compared to analyst estimates of $19.33 million. During the same quarter in the previous year, the business earned ($0.28) earnings per share.

Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. increased their target price on shares of NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. Wells Fargo & Company decreased their price objective on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th. Finally, UBS Group started coverage on shares of NeuroPace in a research note on Tuesday, January 21st. They set a “buy” rating and a $17.00 target price for the company. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, NeuroPace has an average rating of “Moderate Buy” and a consensus target price of $15.33.

NeuroPace Trading Up 4.0 %

Shares of NPCE stock opened at $14.69 on Thursday. NeuroPace has a 1-year low of $5.45 and a 1-year high of $18.15. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. The stock has a 50-day moving average of $11.65 and a 200-day moving average of $8.78.

Insider Activity

In related news, insider Martha Morrell sold 3,200 shares of the company’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $15.01, for a total value of $48,032.00. Following the sale, the insider now owns 87,062 shares in the company, valued at $1,306,800.62. This represents a 3.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 22.20% of the stock is currently owned by company insiders.

Institutional Trading of NeuroPace

Several institutional investors have recently made changes to their positions in NPCE. Financial Advocates Investment Management lifted its stake in NeuroPace by 27.8% in the fourth quarter. Financial Advocates Investment Management now owns 23,000 shares of the company’s stock valued at $257,000 after purchasing an additional 5,000 shares during the last quarter. KCK LTD. purchased a new position in shares of NeuroPace during the 4th quarter valued at $58,981,000. JPMorgan Chase & Co. increased its holdings in NeuroPace by 106.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock worth $84,000 after acquiring an additional 6,181 shares during the last quarter. Barclays PLC raised its stake in NeuroPace by 346.0% in the 3rd quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after acquiring an additional 16,007 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in NeuroPace by 8.7% during the third quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock valued at $2,211,000 after purchasing an additional 25,330 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.